These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6107332)

  • 41. [Iatrogenic extrapyramidal disorders].
    Ludin HP
    Schweiz Med Wochenschr; 1990 Jun; 120(23):855-8. PubMed ID: 1972812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GABA in the striatonigral and striatopallidal systems as moderator and mediator of striatal functions.
    Scheel-Krüger J
    Adv Neurol; 1984; 40():85-90. PubMed ID: 6141713
    [No Abstract]   [Full Text] [Related]  

  • 43. Progabide in the treatment of hyperkinetic extrapyramidal movement disorders.
    Mondrup K; Dupont E; Braendgaard H
    Acta Neurol Scand; 1985 Sep; 72(3):341-3. PubMed ID: 3864333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S
    Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacologic studies of tardive dyskinesia.
    Chase TN; Tamminga CA
    Adv Biochem Psychopharmacol; 1980; 24():457-61. PubMed ID: 7405673
    [No Abstract]   [Full Text] [Related]  

  • 46. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes.
    Dose M; Lange HW
    Pharmacopsychiatry; 2000 Jan; 33(1):19-27. PubMed ID: 10721880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Another view of calcium and extrapyramidal side effects.
    Bailie GR; Nelson MV; Lesar T
    Am J Psychiatry; 1983 Nov; 140(11):1537-8. PubMed ID: 6137965
    [No Abstract]   [Full Text] [Related]  

  • 49. Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and nonclinical approaches.
    May PR; Lee MA; Bacon RC
    Clin Neuropharmacol; 1983; 6 Suppl 1():S35-51. PubMed ID: 6139165
    [No Abstract]   [Full Text] [Related]  

  • 50. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
    Grace AA
    Mov Disord; 2008; 23 Suppl 3():S560-9. PubMed ID: 18781673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is the low incidence of extrapyramidal side-effects of antipsychotics associated with antimuscarinic properties?
    Laduron PM; Leysen JE
    J Pharm Pharmacol; 1978 Feb; 30(2):120-2. PubMed ID: 24098
    [No Abstract]   [Full Text] [Related]  

  • 52. Movement disorders with neuroleptic drug treatment.
    Tarsy D
    Psychiatr Clin North Am; 1984 Sep; 7(3):453-71. PubMed ID: 6148742
    [TBL] [Abstract][Full Text] [Related]  

  • 53. L-Dopa and the treatment of extrapyramidal disease.
    Pelton EW; Chase TN
    Adv Pharmacol Chemother; 1975; 13():253-304. PubMed ID: 1106161
    [No Abstract]   [Full Text] [Related]  

  • 54. Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain.
    Johnson AE; Liminga U; Lidén A; Lindefors N; Gunne LM; Wiesel FA
    Neuroscience; 1994 Dec; 63(4):1003-20. PubMed ID: 7535390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abuse potential of anticholinergics.
    Dose M; Tempel HD
    Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():43-6. PubMed ID: 11072764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
    Glass M; Dragunow M; Faull RL
    Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea.
    Weiner WJ; Goetz CG; Nausieda PA; Klawans HL
    Ann Intern Med; 1978 Mar; 88(3):327-31. PubMed ID: 629494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
    Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
    Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Extrapyramidal syndrome].
    Nakagawa S; Koyama T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):179-82. PubMed ID: 12876960
    [No Abstract]   [Full Text] [Related]  

  • 60. Clinical management of acute neuroleptic-induced extrapyramidal syndromes.
    Keepers GA; Casey DE
    Curr Psychiatr Ther; 1986; 23():139-57. PubMed ID: 2870879
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.